[
  {
    "ts": null,
    "headline": "NSCLC: three trials to keep an eye on",
    "summary": "As the IASLC 2025 World Conference on Lung Cancer approaches, Clinical Trials Arena looks at some of the major Phase III assets you should keep an eye out for.",
    "url": "https://finnhub.io/api/news?id=7f7dbc04ab6456ace50da48024ef833df870cd49aeb255ce50d5d4997f5e3997",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756996615,
      "headline": "NSCLC: three trials to keep an eye on",
      "id": 136641987,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "As the IASLC 2025 World Conference on Lung Cancer approaches, Clinical Trials Arena looks at some of the major Phase III assets you should keep an eye out for.",
      "url": "https://finnhub.io/api/news?id=7f7dbc04ab6456ace50da48024ef833df870cd49aeb255ce50d5d4997f5e3997"
    }
  },
  {
    "ts": null,
    "headline": "Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
    "summary": "Explore Merckâs pipeline and growth strategies from the Wells Fargo",
    "url": "https://finnhub.io/api/news?id=efe3b1853807d71784fa81e1acfbf8b68477a1c436d9a17059c3d3f47bdb53cf",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756996255,
      "headline": "Merck & Co., Inc. (MRK) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript",
      "id": 136638555,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "MRK",
      "source": "SeekingAlpha",
      "summary": "Explore Merckâs pipeline and growth strategies from the Wells Fargo",
      "url": "https://finnhub.io/api/news?id=efe3b1853807d71784fa81e1acfbf8b68477a1c436d9a17059c3d3f47bdb53cf"
    }
  },
  {
    "ts": null,
    "headline": "3 Things You Need to Know if You Buy Pfizer Today",
    "summary": "Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?",
    "url": "https://finnhub.io/api/news?id=2213766ccce6b9991bf12bc13becc1057b10ad016cb0cd3e8c42d37379899bca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756986300,
      "headline": "3 Things You Need to Know if You Buy Pfizer Today",
      "id": 136641988,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "Pfizer has a lofty 6.9% dividend yield, but is it the only or best choice for investors interested in the pharma space?",
      "url": "https://finnhub.io/api/news?id=2213766ccce6b9991bf12bc13becc1057b10ad016cb0cd3e8c42d37379899bca"
    }
  },
  {
    "ts": null,
    "headline": "Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions",
    "summary": "BEIJING, September 04, 2025--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP)",
    "url": "https://finnhub.io/api/news?id=500f26e45ca016b76c6075ff697b04d1c067a8415eb3db4e0122a0dbd06751db",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1756947600,
      "headline": "Biocytogen Enters into Agreement with Merck to Advance Antibody-Conjugated Lipid-Based Delivery Solutions",
      "id": 136641989,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "MRK",
      "source": "Yahoo",
      "summary": "BEIJING, September 04, 2025--Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies and Merck, a leading science and technology company, have entered into an evaluation and option agreement to advance the development of antibody-conjugated lipid-based delivery solutions for nucleic acid payloads, such as antibody-conjugated lipid nanoparticle (LNP)",
      "url": "https://finnhub.io/api/news?id=500f26e45ca016b76c6075ff697b04d1c067a8415eb3db4e0122a0dbd06751db"
    }
  }
]